PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: Abbott
Without An Rx, Some Pharmas Are Skittish
Lower margins and strong-arm direct-to-consumer campaigns are two of the primary barriers to selling nutraceuticals, according to a business school ‘war game’ conducted with the participation of Abbott, Danone (Dannon in the US), GSK and Nestlé. But the global nutraceuticals market – worth $80 billion in 2010, according to Frost & Sullivan – is expected [...]
Posted in Advertising, Global, IP, Marketing, Regulatory, Strategy, patient education Also tagged Consumer Advertising, GlaxoSmithKline, Nutraceuticals 4 Comments
Abbott Shells Out $3.7 Billion for Piramal
In July 2009, judging solely by total revenue, Abbott was assigned the rank of the eighth-largest pharmaceutical company in the Fortune Global 500. Nearly a year later, the company is looking to move up at least a few notches. On May 21, Abbott acquired Indian generic giant Piramal for a cool $2.12 billion up front, [...]
Posted in Strategy Also tagged branded generics, Diabetes, Eli Lilly, Emerging Markets, generics, india, Merck, Oncology, Piramal Leave a comment
Saving Haiti: One Donation at a Time (UPDATED 1/21)
Image by American Red Cross via Flickr
It’s been less than three days since new broke of a massive earthquake in Haiti that all but leveled the struggling country. With thousands dead, a devastated infrastructure, and no emergency plan, countries and businesses around the world have joined in the effort to help the Haitian people with [...]
Posted in News Also tagged American Red Cross, Amgen, Emergency management, Haiti, Health care, Humanitarian aid, Lilly, Red Cross 2 Comments
Abbott to Purchase Solvay for $6.6 Billion (Update 1)
Abbott announced, early Monday morning, that it had signed a deal to purchase Belgium-based drug manufacturer Solvay Pharmaceuticals for $6.6 billion in cash—a mere five months after Solvay’s CEO Werner Cautreels announced that the company was searching for a proper suitor.
The deal adds more than $3 billion in annualized sales to its global pharmaceutical business—three-quarters [...]
New Non-Profit Alliance of Big Pharma Firms